DISCUSSION
cardiovascular disease, ASCVD, hyperglycemia, MetS, T2DM, T2DM.In
CARDIOVASCULAR DISEASE, OTHER METABOLIC DISORDERS, HYPERGLYCEMIA, PRESSURE AREA, TYPE 2 DIABETES, ASCVD
In this pooled data analysis, chiglitazar showed more favorable glycemic control in patients with IR. This is consistent with the proposed mechanism of action of chiglitazar in insulin sensitization. Our investigation, aligning with APT III findings, substantiates the intrinsic link between MetS and IR.Although the frequency of classic cardiovascular risk factors such as elevated levels of low‐density lipoprotein cholesterol and blood pressure are similar in populations with or without T2DM, the unique pathological characteristics of IR and hyperglycemia lead to increased risk of cardiovascular disease in T2DM.In summary, chiglitazar demonstrated efficacy in managing glycemia and modulating lipid profiles among patients with type 2 diabetes. Notably, its effectiveness was more pronounced within subgroups characterized by IR and concomitant MetS. It could be a potential new clinical option to treat patients with T2DM, as well as bring potential benefits for other metabolic disorders and reduce the risk of ASCVD owing to its polypharmacological targeting of multiple mutual risk factors. The sample size used in this subpopulation analysis was limited, and the analysis results need to be further verified in corresponding larger‐scale populations.